X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (462) 462
Newspaper Article (99) 99
Publication (53) 53
Book Review (43) 43
Conference Proceeding (21) 21
Book / eBook (3) 3
Book Chapter (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (271) 271
humans (253) 253
female (169) 169
male (167) 167
cardiac & cardiovascular systems (162) 162
middle aged (156) 156
risk factors (145) 145
abridged index medicus (131) 131
aged (122) 122
diabetes (122) 122
diabetes mellitus (99) 99
mortality (91) 91
cardiovascular disease (90) 90
adult (78) 78
cardiovascular diseases (72) 72
peripheral vascular disease (72) 72
endocrinology & metabolism (68) 68
cardiovascular (61) 61
atherosclerosis (56) 56
heart attacks (56) 56
risk (53) 53
diabetes mellitus, type 2 - drug therapy (50) 50
type 2 diabetes (50) 50
article (49) 49
diabetes mellitus, type 2 - complications (49) 49
treatment outcome (49) 49
care and treatment (48) 48
myocardial infarction (48) 48
analysis (46) 46
hypoglycemic agents - therapeutic use (46) 46
drug therapy (45) 45
cardiology (42) 42
prevalence (39) 39
insulin (38) 38
heart failure (36) 36
patients (36) 36
risk assessment (36) 36
double-blind method (35) 35
follow-up studies (35) 35
health aspects (35) 35
obesity (35) 35
heart attack (34) 34
myocardial-infarction (34) 34
research (34) 34
clinical trials (33) 33
coronary heart disease (33) 33
glucose (33) 33
body mass index (31) 31
patient outcomes (31) 31
diabetics (30) 30
medicine, general & internal (30) 30
mellitus (30) 30
association (28) 28
acute coronary syndromes (27) 27
biomarkers - blood (26) 26
cholesterol (26) 26
diabetes mellitus, type 2 - blood (26) 26
disease (26) 26
internal medicine (26) 26
stroke (26) 26
cardiovascular diseases - epidemiology (25) 25
coronary vessels (25) 25
prognosis (25) 25
cardiovascular diseases - prevention & control (24) 24
complications and side effects (24) 24
death (24) 24
events (24) 24
heart diseases (24) 24
heart-failure (24) 24
hypertension (24) 24
hypoglycemic agents - adverse effects (24) 24
outcomes (24) 24
studies (24) 24
time factors (24) 24
united states - epidemiology (24) 24
acute myocardial-infarction (23) 23
dosage and administration (23) 23
prevention (23) 23
cardiovascular diseases - mortality (22) 22
cerebral infarction (22) 22
cohort studies (22) 22
incidence (22) 22
blood pressure (21) 21
health risk assessment (21) 21
hospitalization (21) 21
angina (20) 20
cardiovascular diseases - etiology (20) 20
cardiovascular-disease (20) 20
complications (20) 20
diabetes therapy (20) 20
myocardial infarction - epidemiology (20) 20
adults (19) 19
cardiac patients (19) 19
glycated hemoglobin a - metabolism (19) 19
population (19) 19
retrospective studies (19) 19
usage (19) 19
women (19) 19
cardiology and cardiovascular medicine (18) 18
coronary artery disease (18) 18
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JAMA - Journal of the American Medical Association, ISSN 0098-7484, 12/2014, Volume 312, Issue 24, pp. 2668 - 2675
Journal Article
NATURE REVIEWS CARDIOLOGY, ISSN 1759-5002, 09/2019, Volume 16, Issue 9, pp. 517 - 518
In a 15-year follow-up of the VADT study, no differences in major cardiovascular outcomes were found among individuals with type 2 diabetes mellitus who... 
GLUCOSE CONTROL | CARDIOVASCULAR OUTCOMES | CARDIAC & CARDIOVASCULAR SYSTEMS | Type 2 diabetes | Complications and side effects | Control | Care and treatment | Blood sugar | Cardiovascular diseases | Health aspects | Risk factors | Methods | Diabetes therapy | Diabetes | Index Medicus
Journal Article
Circulation, ISSN 0009-7322, 12/2017, Volume 136, Issue 25, pp. 2399 - 2399
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 12/2016, Volume 68, Issue 22, p. 2479
  Measurement of glycated hemoglobin (HbA1c), the most widely accepted indicator of long-term glycemic exposure, is central for the diagnosis and management of... 
Laboratories | Mortality | Standardization | Clinical trials | Cardiovascular disease | Glucose | Endorsements | Clinical medicine | Diabetes | Patients
Journal Article
Journal Article
Diabetes Care, ISSN 0149-5992, 09/2018, Volume 41, Issue 9, p. 1981
OBJECTIVE The objective of this study was to evaluate the efficacy and safety of the dual sodium–glucose cotransporter 1 and 2 inhibitor sotagliflozin compared... 
Fasting | Statistical analysis | Diabetes mellitus | Diabetes mellitus (insulin dependent) | Glucose | Hypoglycemia | Insulin | Patients | Placebo effect | Optimization | Weight | Sodium | Safety engineering | Ketoacidosis | Adults | Research design | Diabetes | Safety
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 01/2007, Volume 49, Issue 1, pp. 109 - 116
Objectives: We sought to determine if natriuretic peptides are associated with estrogen and androgen status in a population study of young women without known... 
Body Mass Index | Humans | Middle Aged | Peptide Fragments - blood | Adult | Female | Testosterone - blood | Estrogens - blood | Natriuretic Peptide, Brain - blood | African Americans | Androgens | Hormones | Peptides | Index Medicus | Abridged Index Medicus
Journal Article
JAMA Internal Medicine, ISSN 2168-6106, 2014, Volume 174, Issue 8, pp. 1403 - 1405
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2015, Volume 373, Issue 3, pp. 232 - 242
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2019, Volume 380, Issue 4, pp. 347 - 357
In a randomized trial of patients with type 2 diabetes, treatment with dapagliflozin, an SGLT2 inhibitor that promotes glucosuria, did not result in a higher... 
2013 ACCF/AHA GUIDELINE | MEDICINE, GENERAL & INTERNAL | SELECTIVE SGLT2 INHIBITOR | MANAGEMENT | HEART-FAILURE OUTCOMES | DISEASE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | KIDNEY | EMPAGLIFLOZIN | SOCIETY | Cardiovascular Diseases - etiology | Sodium-Glucose Transporter 2 Inhibitors - therapeutic use | Sodium-Glucose Transporter 2 Inhibitors - adverse effects | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Hospitalization - statistics & numerical data | Male | Benzhydryl Compounds - adverse effects | Cardiovascular Diseases - mortality | Female | Glucosides - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Benzhydryl Compounds - therapeutic use | Heart Failure - epidemiology | Diabetes Mellitus, Type 2 - complications | Glucosides - adverse effects | Type 2 diabetes | Safety and security measures | Dapagliflozin | Dosage and administration | Drug therapy | Cardiovascular diseases | Risk factors | Heart failure | Myocardial infarction | Cerebral infarction | End-stage renal disease | Heart attacks | Mortality | Diabetes mellitus | Cardiovascular disease | FDA approval | Patients | Glomerular filtration rate | Heart rate | Ischemia | Sodium | Arteriosclerosis | Ketoacidosis | Death | Diabetes | Kidney diseases | Safety | Diabetes mellitus (non-insulin dependent) | Heart diseases | Index Medicus | Abridged Index Medicus
Journal Article